QuidelOrtho Corporation logo QDEL - QuidelOrtho Corporation

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 6
HOLD 7
SELL 2
STRONG
SELL 0
| PRICE TARGET: $12.25 DETAILS
HIGH: $12.50
LOW: $12.00
MEDIAN: $12.25
CONSENSUS: $12.25
DOWNSIDE: 26.56%

Stock News

Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm

Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/quidelortho-corp/ Recently a securities fraud complaint was filed against QuidelOrtho on behalf of certain investors who purchased shares of the company's stock between February 17, 2022 and April 1, 2024 (the “Wrongdoing Peri.

Jul 23, 2026 03:00 AM • businesswire.com
QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of restricted stock units ("RSUs") with respect to 356,555 shares of the Company's common stock (the "Inducement Grant") to Micah Young, the Company's Chief Financial Officer and principal financial officer. The Inducement Grant was granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to Mr.

Jul 15, 2026 03:31 PM • prnewswire.com
QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevated

QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevated

QuidelOrtho Corporation continues its steep decline, with over 40% losses since February and a $5B market cap drop since its 2022 merger. QDEL's Q4 and Q1 results both disappointed, with 2026 EPS guidance cut twice in three months and consensus now at $1.85 per share. Profitability struggles are compounded by rising debt, high inventory, weak Chinese sales, and a soft respiratory season, with no clear mitigation strategies outlined.

Jul 08, 2026 04:28 AM • seekingalpha.com
QuidelOrtho Appoints Micah Young as Chief Financial Officer

QuidelOrtho Appoints Micah Young as Chief Financial Officer

Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M.

Jun 23, 2026 03:12 AM • prnewswire.com
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies

QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies

SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients. Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy.

Jun 02, 2026 03:12 AM • prnewswire.com
When Blood Compatibility Becomes a Pregnancy Risk

When Blood Compatibility Becomes a Pregnancy Risk

SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) – a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation.

May 21, 2026 05:18 AM • prnewswire.com
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences

QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences

SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026 Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m.

May 20, 2026 03:00 AM • prnewswire.com
QuidelOrtho Reports First Quarter 2026 Financial Results

QuidelOrtho Reports First Quarter 2026 Financial Results

― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ― ― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ― ― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $620 million, as reported Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.

May 05, 2026 12:05 PM • prnewswire.com

Price Targets